Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram on the vision of patients with retinal degeneration who are being treated with the drug in the management of their concurrent alcohol use disorder.
All sexes, 18 years and older.
Participants must speak English, understand, and sign the informed consent document.
Stated willingness to comply with all study procedures and availability for the duration of the study.
In good general health as evidenced by medical history and with a clinical diagnosis of inherited retinal dystrophy or dry-AMD.
A condition that, in the opinion of the investigator, would preclude participation in the study, e.g., cardiovascular disease, hepatitis.
Individuals with a history of diabetes mellitus.
Individuals with a history of psychosis.
Individuals with hypothyroidism.